Table 1.

Trial characteristics.

Study ID	Study population	Travel destination	Mean age (range)	Treatment (no.)	Control (no.)	Mean treatment duration, d	Overall RoB
Armstrong 2010[15]	US	Turkey	36	Rifaximin (48)	Placebo (47)	14	Low risk of bias
Black 1989[27]	Danish	Egypt	51	Probiotics (47)	Placebo (47)	14	Some concerns
Briand 2006[17]	French	West Africa or Asia	38 (36–40)	Probiotics (79)	Placebo (72)	14	Low risk of bias
de dios Pozo-Olano 1978[19]	US	Mexico	--	Probiotics (26)	Placebo (24)	8	Some concerns
Drakoularakou 2010[12]	British	Varied destinations	38	Probiotics (81)	Placebo (78)	>7	Low risk of bias
Dupont 2005[16]	Mexico	Mexico	--	Rifaximin (54)	Placebo (54)	14	Low risk of bias
Flores 2011[14]	US	Mexico	25 (18–67)	Rifaximin (50)	Placebo (48)	14	Low risk of bias
Hasle 2017[18]	Norwegian	Varied destinations with high risks of TD	43	Probiotics (167)	Placebo (167)	14	Low risk of bias
Hilton 1997[21]	US	Varied destinations	50 (17–80)	Probiotics (126)	Placebo (119)	21	Some concerns
Katelaris 1995[22]	British	Belize	--	Probiotics (181)	Placebo (101)	21	Some concerns
Kollaritsch 1989[24]	Austrian	Varied destinations, hot climates	--	Probiotics (1148)	Placebo (712)	23	Some concerns
Kollaritsch 1993[23]	Austrian	Varied destinations, hot climates	--	Probiotics (655)	Placebo (361)	21	Low risk of bias
Krokowicz 2014[28]	Polish	Varied destinations	--	Probiotics (22)	Placebo (20)	>3	Low risk of bias
Martinez-Sandoval 2010[25]	Mexico	Mexico	24 (18–75)	Rifaximin (99)	Placebo (102)	14	Low risk of bias
Oksanen 1990[26]	Finish	Turkey	43.8 (10–80)	Probiotics (373)	Placebo (383)	14	Some concerns
Virk 2013[13]	US	High TD risk areas	48.7	Probiotics (94)	Placebo (102)	21	Low risk of bias
Zanger 2013[20]	German	Southeast Asia	29 (24–37)	Rifaximin (122)	Placebo (117)	28	Low risk of bias

RoB = risk of bias, TD = travelers’ diarrhea.